Saturday, October 17, 2026
Accelerating medical breakthroughs to patients
Understand new treatments and trials: who they may help, what the evidence shows, and how access differs by country.
Show treatments for
Health Canada/FDA ApprovedUnited States, Canada, Switzerland, European Union
Ojemda (tovorafenib) — once-weekly oral RAF inhibitor for BRAF-altered pediatric low-grade glioma
This is for children and young people — and caregivers — facing relapsed or refractory pediatric low-grade glioma with a BRAF fusion, rearrangement, or V600 mutation after prior systemic therapy.
New treatments and trials, weekly. Every email has an unsubscribe link.
By subscribing, you request Breakthrough Brief emails. Privacy
Special series
Shots, pills, and organ labels in the 2026 weight class — Wegovy injection, Zepbound, the oral maze, and the process line that authorized is not funded. International by default. Zoom by country. Authorized is not funded.
Treatment types